Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study found no relationship between androgenic alopecia and parameters such as PSA level, IPSS, and prostate volume in men over 50.

Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

In this study, long-term low-dose finasteride use in men with alopecia was associated with a significant reduction in the diagnosis of benign prostatic hyperplasia and prostate cancer, although further research is needed to understand the mechanisms and long-term effects.

In this study, high-dose Arachis hypogaea root extract significantly reduced prostate weight and markers of glandular hyperplasia in testosterone-induced BPH in mice, with associated changes in inflammatory gene expression and beneficial shifts in gut microbiota.

This study found that 44.3% of patients with benign prostatic hyperplasia experienced high anxiety levels, which were significantly associated with residual symptoms and demographic factors.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

In this study, Nephrolepis biserrata extract significantly improved fertility indices in male Wistar rats with testosterone propionate-induced benign prostatic hyperplasia, showing increased sperm count and reduced prostate weight, suggesting potential pro-fertility benefits for BPH-related infertility.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

This study found that among male Han Chinese, a higher polygenic risk score was linked to increased risk and poorer treatment outcomes for benign prostatic hyperplasia.

In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This study found that androgenic alopecia may serve as an early marker for benign prostatic hyperplasia.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.

In this experimental study on Holtzman rats with induced benign prostatic hyperplasia, the researchers observed that the extract of Physalis peruviana (aguaymanto) had a greater therapeutic effect on prostate weight reduction and prostatic epithelium height compared to finasteride and terazosine.

This study found no association between androgenetic alopecia and increased prostate volume or serum PSA levels in male patients aged 25–45.